Printer Friendly

FRANK CARY, FORMER IBM CHAIRMAN AND CEO, JOINS CYGNUS BOARD OF DIRECTORS

 FRANK CARY, FORMER IBM CHAIRMAN AND CEO,
 JOINS CYGNUS BOARD OF DIRECTORS
 REDWOOD CITY, Calif., July 16 /PRNewswire/ -- Frank T. Cary, retired IBM chairman and CEO, has been elected to the board of directors of Cygnus Therapeutic Systems (NASDAQ: CYGN), a leader in transdermal drug delivery, the company announced today.
 "We need executives of the caliber of Mr. Cary to help us build Cygnus," said Dr. Gregory B. Lawless, Cygnus president and chief executive officer. "In over 40 years at IBM, Mr. Cary held many positions which have given him a breadth of operating experience which will be valuable to Cygnus as we make the transition from an R&D company to a fully integrated business."
 Frank T. Cary served as IBM's CEO for eight years, and as chairman of the board for 10 years. He joined International Business Machine Corp. as a marketing representative in Los Angeles in 1948. Two years later he was elected an IBM vice president. In 1968, Cary was elected to the IBM board of directors, and became president of the company in 1971.
 Cary is a member of the Visiting Committee of the Harvard University John F. Kennedy School of Government and a member of the Regulatory Advisory Committee of the New York Stock Exchange. He is also a member of the American Academy of Arts and Sciences and The Business Council. He holds an M.B.A. from Stanford University and a B.S. from the University of California, Los Angeles.
 Cary is director of Capital Cities/ABC Inc., Celegene Corp., DNA Plant Technology Inc., ICOS Corp., Lincare Inc., SPS Transaction Services Inc., and Texaco Inc.
 Cygnus is a leader and innovator in the development of advanced transdermal drug delivery systems and is in Redwood City. The Cygnus nicotine transdermal delivery system, Nicotrol(TM), was recently launched into the rapidly expanding nicotine patch market. The company has two other products in advanced clinical trials: an estradiol patch for the treatment of the symptoms of menopause and the prevention of osteoporosis; and a fentanyl patch for moderate to severe post-operative pain management. Cygnus Therapeutic Systems has 11 U.S. patents issued or allowed and over 300 patent applications worldwide covering its transdermal technology.
 -0- 7/16/92
 /CONTACT: Shirley Clayton of Cygnus, 415-599-3552/
 (CYGN) CO: Cygnus Therapeutic Systems ST: California IN: MTC SU: PER


MM-MC -- SF004 -- 9844 07/16/92 08:06 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 16, 1992
Words:399
Previous Article:SCHWAB REPORTS SECOND QUARTER RESULTS
Next Article:WEST ONE EARNINGS UP 28 PERCENT FOR RECORD SECOND QUARTER
Topics:


Related Articles
CYGNUS NAMES NEW PRESIDENT AND CEO FORMER CHIRON PRESIDENT JOINS TO LEAD COMMERCIALIZATION
FORMER IBM CHAIRMAN JOINS SPS BOARD OF DIRECTORS
FORMER CITICORP CHAIRMAN AND CEO WALTER WRISTON JOINS CYGNUS BOARD OF DIRECTORS
'Tapping into the expertise.' (chief executive officers elected as corporate directors) (Welcome to the Board) (Column)
FORMER IBM CHAIRMAN AND CEO FRANK T. CARY JOINS ONTOS BOARD
CYGNUS PROMOTES TWO OFFICERS; ROGER FRANCIS AND ALAN RUSSELL NAMED SENIOR VICE PRESIDENTS
ROCKWELL'S ALAN E. ROSS TO SERVE AS SIA CHAIRMAN; PAT WEBER OF TEXAS INSTRUMENTS ELECTED AS VICE CHAIRMAN
Kenneth L. Chenault.
The Vitality Group Announces Expansion to Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters